|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TTC5 |
Gene summary for TTC5 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TTC5 | Gene ID | 91875 |
| Gene name | tetratricopeptide repeat domain 5 | |
| Gene Alias | NEDCAFD | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q86T04 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 91875 | TTC5 | LZE4T | Human | Esophagus | ESCC | 5.48e-11 | 3.18e-01 | 0.0811 |
| 91875 | TTC5 | LZE24T | Human | Esophagus | ESCC | 1.48e-11 | 2.59e-01 | 0.0596 |
| 91875 | TTC5 | P2T-E | Human | Esophagus | ESCC | 4.28e-23 | 3.10e-01 | 0.1177 |
| 91875 | TTC5 | P4T-E | Human | Esophagus | ESCC | 3.09e-08 | 2.34e-01 | 0.1323 |
| 91875 | TTC5 | P5T-E | Human | Esophagus | ESCC | 2.09e-12 | 2.17e-01 | 0.1327 |
| 91875 | TTC5 | P8T-E | Human | Esophagus | ESCC | 5.85e-17 | 2.35e-01 | 0.0889 |
| 91875 | TTC5 | P9T-E | Human | Esophagus | ESCC | 1.35e-07 | 1.16e-01 | 0.1131 |
| 91875 | TTC5 | P10T-E | Human | Esophagus | ESCC | 1.94e-27 | 3.57e-01 | 0.116 |
| 91875 | TTC5 | P11T-E | Human | Esophagus | ESCC | 4.04e-03 | 2.11e-01 | 0.1426 |
| 91875 | TTC5 | P12T-E | Human | Esophagus | ESCC | 1.11e-34 | 5.82e-01 | 0.1122 |
| 91875 | TTC5 | P15T-E | Human | Esophagus | ESCC | 7.32e-44 | 8.29e-01 | 0.1149 |
| 91875 | TTC5 | P16T-E | Human | Esophagus | ESCC | 2.25e-25 | 3.80e-01 | 0.1153 |
| 91875 | TTC5 | P17T-E | Human | Esophagus | ESCC | 1.42e-02 | 2.12e-01 | 0.1278 |
| 91875 | TTC5 | P19T-E | Human | Esophagus | ESCC | 1.65e-05 | 3.49e-01 | 0.1662 |
| 91875 | TTC5 | P20T-E | Human | Esophagus | ESCC | 1.23e-16 | 2.70e-01 | 0.1124 |
| 91875 | TTC5 | P21T-E | Human | Esophagus | ESCC | 5.63e-18 | 2.02e-01 | 0.1617 |
| 91875 | TTC5 | P22T-E | Human | Esophagus | ESCC | 4.28e-29 | 3.74e-01 | 0.1236 |
| 91875 | TTC5 | P23T-E | Human | Esophagus | ESCC | 3.31e-07 | 2.71e-01 | 0.108 |
| 91875 | TTC5 | P24T-E | Human | Esophagus | ESCC | 1.56e-08 | 1.62e-01 | 0.1287 |
| 91875 | TTC5 | P26T-E | Human | Esophagus | ESCC | 5.26e-28 | 4.77e-01 | 0.1276 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TTC5 | SNV | Missense_Mutation | rs764004831 | c.1150N>T | p.Val384Leu | p.V384L | Q8N0Z6 | protein_coding | deleterious(0.01) | benign(0.041) | TCGA-A2-A1G4-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | adriamycin | SD |
| TTC5 | SNV | Missense_Mutation | rs201731132 | c.1304C>T | p.Ser435Leu | p.S435L | Q8N0Z6 | protein_coding | tolerated(0.23) | benign(0.041) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| TTC5 | SNV | Missense_Mutation | rs746667663 | c.662N>G | p.Ser221Cys | p.S221C | Q8N0Z6 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-BH-A0HX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adrimycin | SD |
| TTC5 | SNV | Missense_Mutation | rs764004831 | c.1150N>T | p.Val384Leu | p.V384L | Q8N0Z6 | protein_coding | deleterious(0.01) | benign(0.041) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| TTC5 | SNV | Missense_Mutation | novel | c.709G>A | p.Glu237Lys | p.E237K | Q8N0Z6 | protein_coding | deleterious(0.01) | possibly_damaging(0.718) | TCGA-C5-A7UI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TTC5 | SNV | Missense_Mutation | rs201731132 | c.1304N>T | p.Ser435Leu | p.S435L | Q8N0Z6 | protein_coding | tolerated(0.23) | benign(0.041) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| TTC5 | SNV | Missense_Mutation | c.80G>A | p.Arg27Gln | p.R27Q | Q8N0Z6 | protein_coding | deleterious(0.01) | probably_damaging(0.96) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| TTC5 | SNV | Missense_Mutation | c.1184N>A | p.Arg395Gln | p.R395Q | Q8N0Z6 | protein_coding | tolerated(0.6) | benign(0) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| TTC5 | SNV | Missense_Mutation | c.164N>G | p.Gln55Arg | p.Q55R | Q8N0Z6 | protein_coding | tolerated(0.44) | benign(0) | TCGA-CA-6718-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
| TTC5 | SNV | Missense_Mutation | c.691G>A | p.Ala231Thr | p.A231T | Q8N0Z6 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |